Trisomy 8 in acute promyelocytic leukaemia: an interphase study by fluorescence in <i>situ</i> hybridization

Kwong, Yok–Lam; Wong, K.F.; Chan, TK

doi:10.1111/j.1365-2141.1995.tb05603.x

Cited by 26 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All consecutive cases of APL diagnosed between 1995 and 2002 were studied. The diagnosis was confirmed with cytogenetic analysis, fluorescence in situ hybridization (Ma et al , 2000) and reverse transcription polymerase chain reaction (RT‐PCR) as reported (Kwong et al , 1995). The short and long PML/RAR α fusion products ( PML break at BCR3 and BCR1 respectively) were determined from the size of RT‐PCR product.…”

Section: Patientsmentioning

confidence: 70%

FLT‐3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact

Au¹,

Fung²,

Chim³

et al. 2004

Br J Haematol

View full text Add to dashboard Cite

Summary FLT‐3 aberrations that occur as an internal tandem duplication (ITD) or a mutation at the activation‐loop position 835, D835, are common in acute promyelocytic leukaemia (APL). We investigated the clinicopathological associations and prognostic impact of FLT‐3 aberrations in a cohort of APL patients. FLT‐3 exons 11 and 12 were amplified by polymerase chain reaction (PCR), and the ITD was recognized as an increase in the size of the PCR product. FLT‐3 exon 17 was amplified, and D835 mutation was identified by loss of an EcoRV site, followed by DNA sequencing. Of 82 patients studied, FLT‐3 aberrations were detected in 35 cases (43%) at diagnosis (ITD: 16; D835 mutation: 18; ITD + D835 mutation: 1). FLT‐3 ITD, but not D835 mutations, was significantly associated with higher presentation white blood cell count (WBC) and microgranular morphology. Early/induction deaths were related to male sex and high presentation WBC. There was a trend for FLT‐3 ITD to be associated with non‐remission (P = 0·06). For disease‐free survival, high WBC was the only significant adverse factor. Male sex, high WBC and FLT‐3 ITD were significant adverse factors for overall survival. These findings have important implications on the possible use of FLT‐3 inhibitors in the treatment of APL.

show abstract

Section: Patientsmentioning

confidence: 70%

FLT‐3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact

Au¹,

Fung²,

Chim³

et al. 2004

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…The diagnosis of APL was based on the World Health Organization criteria, and confirmed by the presence of t(15;17) on karyotyping or fluorescence in‐situ hybridization (FISH), and PML ‐ RARA molecularly. Molecular monitoring for PML ‐ RARA was performed on the peripheral blood by reverse transcription polymerase chain reaction with a sensitivity of 10 −5 as previously reported 12. For newly diagnosed APL, the modified MRC AML12 protocol for AML was used 13.…”

Section: Case Reportsmentioning

confidence: 99%

Angioscopy study from a large patient population comparing sirolimus‐eluting stent with biodegradable versus durable polymer

Chen

Xu²,

Zhang

et al. 2012

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…On reaching a third complete remission (CR3), she was consolidated with idarubicin (Kwong et al , 2001). However, PML/RARA remained positive using a standard reverse transcription polymerase chain reaction (Kwong et al , 1995), with a sensitivity of 1 × 10 −4 . A third haematological relapse occurred 15 months later.…”

Section: Patients and Resultsmentioning

confidence: 99%

Combined arsenic trioxide and all‐trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide

Chim

Lie

et al. 2002

Br J Haematol

Self Cite

View full text Add to dashboard Cite

Summary. The optimal treatment of acute promyelocytic leukaemia (APL) recurring from relapses successfully treated using arsenic trioxide (As 2 O 3 ) is undefined. Three APL patients relapsing from As 2 O 3 -induced remission were studied. Re-treatment with As 2 O 3 failed in one patient in third relapse, and resulted in morphological but not molecular remission in another patient. Combination therapy with As 2 O 3 and all-trans retinoic acid (ATRA), however, resulted in morphological and molecular remission in all three cases, with a follow-up time ranging from 6 to 16 months. Our results suggest a synergistic therapeutic effect between As 2 O 3 and ATRA in APL in advanced relapse.Keywords: relapsed APL, arsenic trioxide, all-trans retinoic acid.Arsenic trioxide (As 2 O 3 ) has been shown to be an effective treatment for patients with relapsed acute promyelocytic leukaemia (APL) (Shen et al, 1997;Soignet et al, 1998;Niu et al, 1999). However, for patients relapsing again after As 2 O 3 -induced remissions, the prognosis is poor. Protocols comprising As 2 O 3 , chemotherapy, all-trans retinoic acid (ATRA) and their various combinations have limited success (Niu et al, 1999). Therefore, there is a need to define effective treatment strategies for these patients.In a cohort of 17 consecutive cases of APL in relapse treated with intravenous As 2 O 3 followed by consolidation with idarubicin alone (Kwong et al, 2001), five patients had relapsed again. Two patients died of central nervous system bleeding before further treatment could be given (Au et al, 2000). The remaining three patients were successfully treated with a combination of As 2 O 3 and ATRA, and are the subjects of this report. PATIENTS AND RESULTSCase 1 was a 41-year-old woman treated with As 2 O 3 for APL in second relapse (Table I). On reaching a third complete remission (CR3), she was consolidated with idarubicin (Kwong et al, 2001). However, PML/RARA remained positive using a standard reverse transcription polymerase chain reaction (Kwong et al, 1995), with a sensitivity of 1 · 10 )4. A third haematological relapse occurred 15 months later. Re-treatment with As 2 O 3 (10 mg/d) was ineffective, as evidenced by persistent leukaemia (pancytopenia and 40% blasts and promyelocytes in the marrow) after 42 d of therapy. ATRA (45 mg/m 2 /d) was then added. After 2 weeks of combined As 2 O 3 /ATRA treatment, the promyelocytes in the marrow had decreased to 5%. The treatment was stopped after 76 d of As 2 O 3 and 33 d of ATRA. At this point, the marrow was in complete morphological remission, but PML/RARA was still detectable. Three more monthly courses of As 2 O 3 /ATRA (each for 14 d) were administered, with PML/RARA becoming negative after the first course. At the latest follow-up 16 months after CR4, the patient was in haematological and molecular remission.Case 2 was a 21-year-old woman with APL in first relapse, who achieved a CR2 with As 2 O 3 (Table I). PML/ RARA remained positive despite consolidation with idarubicin, and a second haematological rel...

show abstract

Trisomy 8 in acute promyelocytic leukaemia: an interphase study by fluorescence in situ hybridization

Cited by 26 publications

References 10 publications

FLT‐3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact

FLT‐3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact

Angioscopy study from a large patient population comparing sirolimus‐eluting stent with biodegradable versus durable polymer

Combined arsenic trioxide and all‐trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide

Contact Info

Product

Resources

About